Disrupting the Inflammation Process
Wednesday December 4, 2019
Abcentra is leveraging cutting-edge science to develop a portfolio of novel antibody therapeutics for serious inflammatory diseases, where new treatments are critically needed. Chronic inflammation is often the underlying cause of several diseases and conditions including; cancers, rheumatoid arthritis, atherosclerosis, and other cardiovascular diseases. Without intervention, the inflammation process has the potential to last extended periods of time.
Chronic inflammation is an immune response and often begins with the exposure to a harmful substance. This is when the body believes your cells are in trouble and local immune cells start to fight back. Then, it morphs into a lingering state that persists for months or years. Over time, this can lead to DNA damage, tissue death, and internal scarring. Progression from acute to chronic inflammation can result from persistent injury or individual factors such as diabetes, rheumatoid diseases or other cardiovascular diseases.
Inflammation is a primary driver behind many fatal and life-threatening diseases. Current treatment options can be suboptimal, and thus patients are at risk for prolonged damage. However, Abcentra is finding new ways to address the underlying inflammation associated with these diseases. Oxidized low density lipoprotein (oxLDL) is implicated in common, chronic conditions caused by inflammation such as cardiovascular disease, rheumatological diseases and cancer. Our lead candidate, orticumab, targets oxLDL to treat plaque psoriasis and accelerated atherosclerosis in patients with rheumatoid disease. Three clinical trials have been completed to date, demonstrating an excellent safety profile and evidence of activity in humans.
By targeting inflammation, Abcentra hopes to alleviate symptoms and treat diseases, creating a fuller life for patients. These types of efforts must continue in order to bring life-saving treatment options to patients. From new therapeutic recommendations, to assessing the safety and efficacy of given therapeutics, and continuing our education efforts, we must continue evaluating the new frontier of therapeutic areas to create a better life for patients.
Read more about our lead candidate, orticumab, here, and learn more about treatment options currently in development that disrupt the inflammation process and help patients manage their conditions.